NANO Nordic Nanovector ASA

Nordic Nanovector ASA: Mandatory Notification of Trade - Primary Insiders

Nordic Nanovector ASA (OSE: NANO) (OSE: NANOO)

Reference is made to the stock exchange notice issued by Nordic Nanovector ASA (the "Company") on 8 December 2016 regarding the management's share purchases in the Company. After the notice was published, the members of management have made the following transactions:

On 8 December 2016, Luigi Costa, CEO of Nordic Nanovector ASA purchased 5,929 shares in Nordic Nanovector ASA at an average price of NOK 114.00 per share. Following this transaction, Luigi Costa own 79,115 shares in Nordic Nanovector ASA and holds 1,088,106 options in the company.

On 8 December 2016, Tone Kvåle, CFO of Nordic Nanovector ASA purchased 1,754 shares in Nordic Nanovector ASA at an average price of NOK 114.00 per share. Following this transaction, Tone Kvåle and related parties will together own 179,608 shares in Nordic Nanovector ASA and Tone Kvåle holds 210,000 options in the company.

On 8 December 2016, Lisa Rojkjaer, Chief medical officer of Nordic Nanovector ASA purchased 2,186 shares in Nordic Nanovector ASA at an average price of NOK 114.00 per share. Following this transaction, Lisa Rojkjaer owns 2,186 shares in Nordic Nanovector ASA and holds 340,000 options in the company.

On 8 December 2016, Anniken Hagen, Chief technical and operations officer of Nordic Nanovector ASA purchased 1,754 shares in Nordic Nanovector ASA at an average price of NOK 114.00 per share. Following this transaction, Anniken Hagen owns 63,858 shares in Nordic Nanovector ASA and holds 142,000 options in the company.

On 8 December 2016, Rita Dege, Chief human resources officer of Nordic Nanovector ASA purchased 1,754 shares in Nordic Nanovector ASA at an average price of NOK 114.00 per share. Following this transaction, Rita Dege owns 4,754 shares in Nordic Nanovector ASA and holds 32,000 options in the company.

This information is subject to duty of disclosure pursuant to Section 4-2 of the Norwegian Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

EN
09/12/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nordic Nanovector ASA

Patrik Ling
  • Patrik Ling

Nordic Nanovector (No_rec, TP: NOK) - Discontinuing coverage

We have discontinued coverage of Nordic Nanovector due to a reallocation of analyst resources. Our last published recommendation, target price and estimates should no longer be relied upon.

Patrik Ling
  • Patrik Ling

Nordic Nanovector (No_rec, TP: NOK) - Proposed merger with APIM Therap...

Nordic Nanovector has concluded its strategic review, and the outcome is a proposed merger with the unlisted Norwegian company APIM Therapeutics. Under the proposed terms of the merger, the owners of APIM Therapeutics are set to have c76% of the combined entity, while Nordic Nanovector’s owners would have c24%. An EGM has been scheduled for 1 December or thereabouts and, if approved, the transaction should close in late Q4. We have removed our recommendation and target price following the strate...

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Gonzalo Artiach

Nordic Nanovector - Terminating coverage

ABGSC ceases coverage of Nordic Nanovector SELL is our final recommendation NOK 1.5 is our final target price

Patrik Ling
  • Patrik Ling

Nordic Nanovector (Hold, TP: NOK1.60) - Limited visibility on strategi...

The decision to terminate the PARADIGME phase IIb trial in Q2 clearly has major repercussions for Nordic Nanovector given it was the most mature development project in its pipeline. Operations have already been drastically downsized, with c70% of personnel laid off. No new data or real explanation for the weak efficacy in the trial was given, and with limited value in the early-stage pipeline in our view, we value the company at its end-2022e cash position. We reiterate our HOLD and NOK1.6 targe...

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Gonzalo Artiach

Nordic Nanovector - Q2 report

Company restructure leads to 70% staff reduction NOK ~185m in study closing costs leaves NOK ~100m Webcast today at 8:30 am CET

ResearchPool Subscriptions

Get the most out of your insights

Get in touch